biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by sometoaston Mar 16, 2015 10:41am

150 Views

Post# 23525029

RE:this opens up

Rob's phone might also be busy answering questions about why Thursday and Friday were such busy buying days (seems to me that people who sold those days could have a legitimate beef if there was a news leak). Volume spikes should be avoided before a news release. On a more scientific note, I am wondering if other peptides are likely to also deliver RNAi past the BBB? In other words, is there an easy work around BTI's IP? Don't get me wrong - I think this is great news.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity